New cancer drug begins human testing
NCT ID NCT06512116
Summary
This early-stage trial is testing a new drug called SIBP-A17 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers will give increasing doses to 196 participants to find the safest amount and learn how the body processes the drug. The study focuses on safety and proper dosing rather than proving effectiveness against cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.